These BRAFV600-mutant monomers are targeted by class I or monomer-selective BRAF inhibitors (BRAFi), approved for use in combination with MEK inhibitors (MEKi) in BRAFV600-mutant melanoma. This evidence concerns the gene BRAF and melanoma.